Hematopoietic Stem Cell Transplant for Mycosis Fungoides and Sezary Syndrome

被引:32
作者
Virmani, Pooja [1 ]
Zain, Jasmine [2 ]
Rosen, Steven T. [2 ]
Myskowski, Patricia L. [1 ]
Querfeld, Christiane [2 ,3 ,4 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Dermatol Serv, New York, NY 10022 USA
[2] City Hope Comprehens Canc Ctr, Dept Hematol Hematopoiet Cell Transplantat, Duarte, CA 91010 USA
[3] City Hope Comprehens Canc Ctr, Dept Pathol, Duarte, CA 91010 USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY 10022 USA
关键词
Cutaneous T-cell lymphoma; Mycosis fungoides; Sezary syndrome; Autologous hematopoietic stem cell transplant; Allogeneic hematopoietic stem cell transplant; Myeloablative; Reduced-intensity conditioning; BONE-MARROW-TRANSPLANTATION; CUTANEOUS-LYMPHOMAS; INTERNATIONAL-SOCIETY; PROGNOSTIC-FACTORS; WORKING PARTY; BLOOD; GRAFT; DISEASE; CLASSIFICATION; ORGANIZATION;
D O I
10.1016/j.det.2015.05.014
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Mycosis fungoides (MF) and Sezary syndrome (SS) are common types of primary cutaneous T-cell lymphoma. Early-stage MF has a favorable prognosis and responds well to skin-directed regimens. Patients with advanced-stage MF, transformed MF, and SS are treated with combined systemic and skin-directed therapies. However, the disease is incurable with standard regimens, and frequent relapses are common. Owing to the lack of improvement in overall survival with standard regimens, hematopoietic stem cell transplant (HSCT) has been explored as a potential curative option. This article reviews the role of HSCT in MF/SS and discusses data regarding conditioning regimens, treatment-related complications, and outcomes.
引用
收藏
页码:807 / +
页数:13
相关论文
共 53 条
[1]   Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sezary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal [J].
Agar, Nita Sally ;
Wedgeworth, Emma ;
Crichton, Siobhan ;
Mitchell, Tracey J. ;
Cox, Michael ;
Ferreira, Silvia ;
Robson, Alistair ;
Calonje, Eduardo ;
Stefanato, Catherine M. ;
Wain, Elizabeth Mary ;
Wilkins, Bridget ;
Fields, Paul A. ;
Dean, Alan ;
Webb, Katherine ;
Scarisbrick, Julia ;
Morris, Stephen ;
Whittaker, Sean J. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) :4730-4739
[2]  
Alpdogan O, 2013, DISCOV MED, V16, P159
[3]   TREATMENT OF MURINE LEUKAEMIA WITH X-RAYS AND HOMOLOGOUS BONE MARROW - PRELIMINARY COMMUNICATION [J].
BARNES, DWH ;
CORP, MJ ;
LOUTIT, JF ;
NEAL, FE .
BRITISH MEDICAL JOURNAL, 1956, 2 (SEP15) :626-627
[4]   Reduced-Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan for Patients With Acute Myeloid Leukemia: A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation [J].
Baron, Frederic ;
Labopin, Myriam ;
Peniket, Andy ;
Jindra, Pavel ;
Afanasyev, Boris ;
Sanz, Miguel A. ;
Deconinck, Eric ;
Nagler, Arnon ;
Mohty, Mohamad .
CANCER, 2015, 121 (07) :1048-1055
[5]  
Baronciani D, 2015, HEMATOL ONC IN PRESS
[6]  
Bearman Scott I, 2003, Curr Hematol Rep, V2, P277
[7]  
Bensinger WI, 2009, THOMAS HEMATOPOIETIC, P316
[8]  
BIGLER RD, 1991, BONE MARROW TRANSPL, V7, P133
[9]  
CHEN Y-C, 1986, Taiwan yixuehui zazhi, V85, P304
[10]   Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas [J].
de Masson, Adele ;
Beylot-Barry, Marie ;
Bouaziz, Jean-David ;
de Latour, Regis Peffault ;
Aubin, Francois ;
Garciaz, Sylvain ;
d'Incan, Michel ;
Dereure, Olivier ;
Dalle, Stephane ;
Dompmartin, Anne ;
Suarez, Felipe ;
Battistella, Maxime ;
Vignon-Pennamen, Marie-Dominique ;
Rivet, Jacqueline ;
Adamski, Henri ;
Brice, Pauline ;
Francois, Sylvie ;
Lissandre, S Verine ;
Turlure, Pascal ;
Wierzbicka-Hainaut, Ewa ;
Brissot, Eolia ;
Dulery, Remy ;
Servais, Sophie ;
Ravinet, Aurelie ;
Tabrizi, Reza ;
Ingen-Housz-Oro, Saskia ;
Joly, Pascal ;
Socie, Gerard ;
Bagot, Martine .
HAEMATOLOGICA, 2014, 99 (03) :527-534